BTK inhibitor

News

Roche trumpets new fenebrutinib data in relapsing MS

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (M

News

Novartis gets a win in chronic hives, setting up filings

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a su

News

Roche’s BTK drug fenebrutinib hits the mark in MS

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv

News

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Germany’s Merck KGaA said this morning that the FDA has placed a partial clinical hold on its multiple sclerosis drug candidate evobrutinib, vying to become a new oral the

News

Sanofi drops BTK drug tolebrutinib in myasthenia gravis

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso

News

Lilly breaks new ground for BTK class with Jaypirca approval

Eli Lilly has picked up an FDA approval for its non-covalent BTK inhibitor Jaypirca in relapsed mantle cell lymphoma (MCL) patients who relapse after treatment with current drugs in the cla

Roche trumpets new fenebrutinib data in relapsing MS

Novartis gets a win in chronic hives, setting up filings

Roche’s BTK drug fenebrutinib hits the mark in MS

FDA slaps clinical hold on Merck’s MS drug evobrutinib

Sanofi drops BTK drug tolebrutinib in myasthenia gravis

Lilly breaks new ground for BTK class with Jaypirca approval

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

BTK inhibitor

Editor's Picks